We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Mesoblast Ltd (MESO) ADR Each Representing 10 Ord Shares SPON

Sell:$18.02 Buy:$18.19 Change: $1.20 (7.05%)
NASDAQ:0.04%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$18.02
Buy:$18.19
Change: $1.20 (7.05%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$18.02
Buy:$18.19
Change: $1.20 (7.05%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.

Contact details

Address:
L 38 55 Collins St
MELBOURNE
3000
Australia
Telephone:
+61 (3) 96396036
Website:
https://www.mesoblast.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
MESO
ISIN:
US5907174016
Market cap:
$1.82 billion
Shares in issue:
1.14 billion
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Silviu Itescu
    Chief Executive Officer, Executive Director
  • William Burns
    Non-Executive Independent Vice Chairman of the Board
  • Andrew Chaponnel
    Interim Chief Financial Officer
  • Fiona See
    Senior Vice President, Head - Translational Research
  • Peter Howard
    General Counsel, Corporate Executive
  • Eric Rose
    Executive Director, Chief Medical Officer
  • Justin Horst
    Head - Manufacturing
  • Michael Schuster
    Pharma Partnering
  • Geraldine Storton
    Head - Regulatory Affairs and Quality Management
  • Paul Hughes
    Joint Company Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.